People having hematological disorders and hypercoagulability state need extra precautions because of the increased risk of thrombosis after COVID-19 vaccination

Aydemir, Duygu; Ulusu, Nuriye Nuray

doi:10.3389/fmed.2022.1082611

Front. Med.

2023

DOI: 10.3389/fmed.2022.1082611

|View full text |Cite

People having hematological disorders and hypercoagulability state need extra precautions because of the increased risk of thrombosis after COVID-19 vaccination

Duygu Aydemir

Nuriye Nuray Ulusu²

Abstract: Aydemir D and Ulusu NN () People having hematological disorders and hypercoagulability state need extra precautions because of the increased risk of thrombosis after COVIDvaccination.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

COVID-19 treatment: Nattokinase, a fibrinolytic serine protease is the low-hanging fruit

Okeahialam

2024

Santosh University Journal of Health Sciences

View full text Add to dashboard Cite

COVID-19 infection was first reported in 2019 and was shortly declared a pandemic. Without ample time for targeted research into therapy, various existing drugs were tried with limited success and vaccines speedily emerged. Although with serious consequences in some instances, vaccination brought relief as a public health measure. Before long, breakthrough infections were recorded postvaccination and protection waned with time. With new cases still being recorded, it has become necessary to try more agents with the potential for therapeutic benefits. In viral infections, it is the immune consequences that kill and not the viruses. Therefore in treatment, it is either the body is protected from the infection or the immune consequences. The phase of infection is preclinical and may go unnoticed. Once symptoms appear it is the immune consequences that the body is left to grapple with. That may be why antiviral agents when symptoms appear is too little too late. Victims of COVID-19 infection die from the perturbation of the clotting and fibrinolytic pathways resulting in ineffective oxygenation of the tissues from extensive microthrombi. Therefore, anything that would lyse the microthrombi and allow tissue perfusion should hold the aces. This is where Nattokinase, a fibrinolytic serine protease comes in. It counters Plasminogen Activator Inhibitor-1 which levels mirror disease severity and gives tissue plasminogen activator freedom to lyse the fibrin that clogs the vasculature. This is at the center of the disease pathophysiology and saves the infected individual.

show abstract

COVID-19 treatment: Nattokinase, a fibrinolytic serine protease is the low-hanging fruit

Okeahialam

2024

Santosh University Journal of Health Sciences

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

People having hematological disorders and hypercoagulability state need extra precautions because of the increased risk of thrombosis after COVID-19 vaccination

Abstract: Aydemir D and Ulusu NN () People having hematological disorders and hypercoagulability state need extra precautions because of the increased risk of thrombosis after COVIDvaccination.

Cited by 1 publication

References 56 publications

COVID-19 treatment: Nattokinase, a fibrinolytic serine protease is the low-hanging fruit

COVID-19 treatment: Nattokinase, a fibrinolytic serine protease is the low-hanging fruit

Contact Info

Product

Resources

About